Life sciences company ValiRx (LON:VAL) has unveiled Dr Alan Boyd as medical monitoring officer for the clinical development of VAL201.
The company said the pharmaceutical physician will oversee the medical aspects of the clinical trials and development of VAL201, including input into the final protocol, interaction with the regulatory agencies, medical oversight on patient recruitment and follow-up activity.
Boyd has over 30 years’ experience in clinical drug development, having worked for GlaxoSmithKline (LON:GSK) and Zeneca Group in the past.
He is also currently a chairman of the Specialist Advisory Committee in Pharmaceutical medicine at the Royal College of Physicians.
It comes after Professor Hilary Calvert was appointed as clinical advisor for the development of VAL201.
It is hoped the company’s potentially breakthrough treatment for cancer will tackle a number of strands of the disease, including breast, ovarian and prostate forms.
In an update on its progress, ValiRx said scale-up activity and the manufacture of sufficient amounts of clinical grade compound for the initial VAL201 clinical trials have been completed.
The protocols that have been developed for the trials are being refined and agreed, while the company has completed its identification and targeting o potential patient populations.
ValiRx chief executive Dr Satu Vainikka said: “2013 will be a very exciting year for ValiRx as we are progressing our clinical development and expanding our cancer therapeutic portfolio.
“I am delighted to be working with internationally recognised experts in Oncology and we at ValiRx are already feeling the benefit of their collaboration, counsel and support.
“The next stage of ValiRx's development and growth will see a very exciting step change.”
